Bicycle Therapeutics plc (50BA) - Total Assets
Based on the latest financial reports, Bicycle Therapeutics plc (50BA) holds total assets worth €606.58 Million EUR (≈ $709.15 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Bicycle Therapeutics plc - Total Assets Trend (2018–2025)
This chart illustrates how Bicycle Therapeutics plc's total assets have evolved over time, based on quarterly financial data. Also see 50BA market cap overview for the company's overall valuation and market capitalisation.
Bicycle Therapeutics plc - Asset Composition Analysis
Current Asset Composition (December 2025)
Bicycle Therapeutics plc's total assets of €606.58 Million consist of 95.2% current assets and 4.8% non-current assets. Review debt load of Bicycle Therapeutics plc to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 87.5% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Bicycle Therapeutics plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See today's stock price for Bicycle Therapeutics plc for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bicycle Therapeutics plc's current assets represent 95.2% of total assets in 2025, an increase from 94.1% in 2018.
- Cash Position: Cash and equivalents constituted 87.5% of total assets in 2025, up from 77.7% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Bicycle Therapeutics plc Competitors by Total Assets
Key competitors of Bicycle Therapeutics plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
USA | $1.21 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $1.07 Billion |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $543.64 Million |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
USA | $246.58 Million |
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
USA | $235.36 Million |
Bicycle Therapeutics plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 12.08 | 10.39 | 9.04 |
| Quick Ratio | 12.08 | 10.39 | 9.04 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €527.60 Million | €726.84 Million | €242.69 Million |
Bicycle Therapeutics plc - Advanced Valuation Insights
This section examines the relationship between Bicycle Therapeutics plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.56 |
| Latest Market Cap to Assets Ratio | 0.26 |
| Asset Growth Rate (YoY) | -25.0% |
| Total Assets | €717.60 Million |
| Market Capitalization | $186.10 Million USD |
Valuation Analysis
Below Book Valuation: The market values Bicycle Therapeutics plc's assets below their book value (0.26x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Bicycle Therapeutics plc's assets decreased by 25.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Bicycle Therapeutics plc (2018–2025)
The table below shows the annual total assets of Bicycle Therapeutics plc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €717.60 Million ≈ $838.95 Million |
-25.01% |
| 2024-12-31 | €956.87 Million ≈ $1.12 Billion |
+60.73% |
| 2023-12-31 | €595.34 Million ≈ $696.02 Million |
+44.99% |
| 2022-12-31 | €410.61 Million ≈ $480.05 Million |
-14.42% |
| 2021-12-31 | €479.79 Million ≈ $560.93 Million |
+197.73% |
| 2020-12-31 | €161.15 Million ≈ $188.40 Million |
+46.24% |
| 2019-12-31 | €110.19 Million ≈ $128.83 Million |
+35.00% |
| 2018-12-31 | €81.63 Million ≈ $95.43 Million |
-- |
About Bicycle Therapeutics plc
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide … Read more